AdAlta Ltd. (AU:1AD) has released an update.
AdAlta Ltd has partnered with Cell Therapies Pty Ltd (CTPL) to advance its cellular immunotherapy initiatives, aiming to bring innovative Asian treatments to global markets using AdAlta’s i-body technology. The partnership will enable rapid development and manufacturing capabilities, ensuring adherence to western regulatory standards. This strategic collaboration is poised to streamline the process from in-licensing to clinical trial manufacturing, marking a significant step towards delivering new cancer therapies.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.
